Tanvex is a vertically-integrated company, with end-to-end capabilities from R&D through to commercialization.
Cell line development and characterization, master cell selection and cell “seeds” are produced in the company’s Taiwan-based lab, while second generation upstream development takes place in the U.S. facility, where working cell banks are grown and reproduced in quantity, and monitored for stability, expression level, and the physical and biologic properties most similar to the reference products, preparatory to harvest. Downstream activities including purification and packaging take place in-house in the U.S. plant. The facility also incorporates warehouse space for storage of product prior to distribution.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze